A new, large-scale, Danish Study compared three leading HPV self-sampling devices in almost 2000 women, showing comparable analytical and diagnostic quality, great overall agreement, maintained sample stability, and consistent performance across age groups. These findings the reliability of HPV self-sampling and open the way for broader analysis and discussion in which device choice should be guided by cost, user preferences, and logistics rather than sample quality.
From treatment to prevention, an established switch
Cervical cancer remains a preventable disease whose incidence can be dramatically reduced by HPV vaccination and screening. Yet sustained gaps in access and participation persist, particularly among underscreened groups who face practical, cultural, or privacy barriers to clinic-based testing. Self-sampling for HPV has emerged as one of the most reliable ways to remove barriers and increase participation, and international guidance now recognizes self-collected vaginal specimens as clinically equivalent to clinician-collected samples. Systematic reviews and implementation reports emphasize the high acceptance of self-collected vaginal swabs across diverse populations and healthcare settings, and cost-effectiveness analyses indicate that HPV self-sampling can lower the cost per complete screen, a critical factor for scaling programs while maintaining quality.
The study rationale: design, scale, and what was measured
The Danish article published last December was included in a real-world HPV screening program workflow and framed as a prospective diagnostic accuracy study aligned with the STARD guideline. Women aged 23–64 who opted for HPV self-sampling received paired devices in three combinations:
- Evalyn® Brush + Vaginal self-FLOQSwabs®
- Evalyn + SensiGrip Vaginal self-FLOQSwabs®
- Vaginal self-FLOQSwabs® + SensiGrip Vaginal self-FLOQSwabs®
Returned kits were processed on the BD COR platform with the BD Onclarity HPV assay. The study assessed: (a) internal‑control performance; (b) analytical and diagnostic HPV agreement; (c) genotype-specific concordance; (d) potential effects of time‑to‑analysis, age, and sampling order on quality.
Out of 1,766 paired kits returned, 1,677 met the inclusion criteria for concordance analysis, providing robust evidence on the diagnostic accuracy of HPV self-sampling devices.
What the Study Found: Device Performance
HPV detection showed consistent, high analytical agreement across devices (no cut-off applied): 93.5% for Evalyn versus FLOQSwabs, 94.1% for Evalyn versus SensiGrip, and 95.0% for FLOQSwabs versus SensiGrip. When diagnostic cut‑offs were applied, agreement increased to 97.8%, 96.5%, and 97.4%, respectively. Genotype‑level diagnostic and analytical agreement reached at least 98% for all device pairings, accompanied by kappa values predominantly in the “good” to “excellent” range. In clinical terms, the evidence indicates that all HPV self-sampling devices perform similarly in both sample quality and HPV detection. Regarding real-world stability within mail-back windows, housekeeping gene values remained stable across devices over 14 days, reflecting strong HPV sample stability during transport; data beyond 2 weeks were heterogeneous but did not suggest a distinct decline. This reflects actual program timelines, in which timely returns are the norm when participation is well organized. To summarize, in a high-volume, validated testing workflow, Evalyn, FLOQSwabs, and SensiGrip yield comparable sample quality and detection performance, suggesting that HPV screening programs can focus on other criteria when choosing the right device, such as cost, user preference, packaging, and logistics.
Pre-Analytical Robustness of Dry Swabs
Other papers have already addressed a long-standing question: how robust are self-collected dry swabs to time and temperature during transport? In one of the studies, researchers compared self-collected vaginal dry swabs with clinician-collected cervical samples, then stress-tested dry swabs under ambient storage for up to 30 days and simulated summer (up to 40 °C) and winter (down to 10 °C) thermal cycles. Results showed high overall agreement of approximately 90% and a positive percentage agreement of about 84% between self-collected and clinician-collected samples. There was no observable relationship between the number of days the swabs were stored dry (up to roughly 41 days) and HPV amplification; while housekeeping gene levels may decline with prolonged storage or exposure to thermal stress, this behavior mainly reflects cellularity rather than any loss of HPV target material. Even under thermal extremes, internal control Ct values were affected, but HPV detection remained within expected analytical limits. These findings support the operational resilience of mail-back HPV testing strategies and provide reassurance to laboratory and program managers that HPV self-sampling remains analytically robust under realistic transport conditions.
Health‑System Perspective: Cost, Capacity, and Coverage
Scaling HPV self-sampling can be economically advantageous. An economic evaluation tailored to England’s NHS Cervical Screening Programme modeled three strategies across a cohort of 10,000 people:
- Cost per complete screen:
- Clinician‑collected: £56.81
- Self‑collected first‑void urine: £38.57
- Self‑collected vaginal swab: £40.37
In plausible uptake scenarios, e.g., +15% among non-attenders and 50% of current attenders converting to converting to HPV self-sampling, the NHS could save £16.5–£19.2 million per 3-year cycle, while increasing the number of complete screens. Anyway, there are caveats: because many programs still require cytology triage on a clinician-collected sample when the self-sample is HPV‑positive, an extra step can increase loss‑to‑follow-up. However, the impact remains favorable: HPV self-sampling lowers per-screen costs and, with thoughtful design (e.g., reminders, navigation, or molecular triage in the future), can increase coverage and reduce clinic capacity pressure.
What does this study mean for screening programs
First of all, device choice in HPV self-sampling programs can focus on user-centric and operational factors. Given comparable analytical and diagnostic performance across the devices, decision‑makers can optimize for cost, packaging, size/weight, and user preference without compromising quality. Second, wherever operationally feasible, dry transport simplifies logistics and supports HPV sample stability, reducing risks linked to liquid media. Third, in systems that still require clinician cytology after a positive self-sample, the key is navigation: clear instructions, rapid result delivery, easy booking, and SMS/app reminders can substantially reduce the need for a second follow-up. Finally, with lower cost per complete screen, HPV self-sampling helps expand cervical cancer screening coverage while containing expenses, especially as vaccinated cohorts age into screening.
Other findings and conclusions
Does age affect self-sample quality?
Not materially. The Danish study found only minor housekeeping gene expression differences across age strata, within expected technical variation. This is a benefit compared to cytology, where atrophic changes can complicate interpretation in older age.
Which device is “best”?
From a sample‑quality and detection perspective, the three HPV self-sampling devices analyzed in the Danish study performed similarly. Programs can therefore select the device based on costs, women’s preference, inclusion, and logistics. For example, compact kits that reduce postage weight or ergonomic designs that increase confidence and usability.
Will self-sampling lower overall costs?
Modeling indicates a 28–32% reduction in the cost per complete screen with HPV self-sampling versus clinician collection, alongside significant projected savings.
The evidence supporting HPV self-sampling is robust: in this 1,677‑participant comparison, the three products produced comparable sample quality and HPV detection; dry swabs retained analytical integrity across mail-back timelines and temperature stresses; and economic models show significant savings when self-sampling is integrated into national programs at scale. In conclusion, sample quality should no longer be the deciding factor when choosing a device for HPV self-sampling. Instead, health systems and providers should focus on acceptability, logistics, cost, and follow-through, the factors that truly determine coverage, equity, and long-term sustainability in the mission to eliminate cervical cancer.
References
- Arum A, Andreasen EK, Pedersen H, et al. Large-Scale Study Comparing Analytical and Diagnostic Quality of Three HPV Self-Sampling Devices for At-Home Cervical Cancer Screening. APMIS. 2025 Dec;133(12):e70109.
- Qi M, Naranjo AR, Duque AJ, et al. Evaluation of Pre-Analytical Variables for Human Papillomavirus Primary Screening from Self-Collected Vaginal Swabs. J Mol Diagn. 2024 Jun;26(6):487-497.
- Huntington S, Puri Sudhir K, Schneider V, et al. Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation. BMJ Open. 2023 Jun 6;13(6):e068940.
Join CoScience HUB
Create your CoScience HUB account now to access cutting-edge science and position yourself at the forefront of innovation.
Sign Up Now
